PL2852671T3 - Wytwarzanie ludzkich komórek ips z użyciem syntetycznego samoreplikującego się rna - Google Patents
Wytwarzanie ludzkich komórek ips z użyciem syntetycznego samoreplikującego się rnaInfo
- Publication number
- PL2852671T3 PL2852671T3 PL13794196T PL13794196T PL2852671T3 PL 2852671 T3 PL2852671 T3 PL 2852671T3 PL 13794196 T PL13794196 T PL 13794196T PL 13794196 T PL13794196 T PL 13794196T PL 2852671 T3 PL2852671 T3 PL 2852671T3
- Authority
- PL
- Poland
- Prior art keywords
- generation
- ips cells
- human ips
- replicative rna
- synthetic self
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1241—Nucleotidyltransferases (2.7.7)
- C12N9/127—RNA-directed RNA polymerase (2.7.7.48), i.e. RNA replicase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
- C12N2501/602—Sox-2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
- C12N2501/603—Oct-3/4
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
- C12N2501/604—Klf-4
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
- C12N2501/605—Nanog
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
- C12N2501/606—Transcription factors c-Myc
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
- C12N2506/1307—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from adult fibroblasts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36141—Use of virus, viral particle or viral elements as a vector
- C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
- C12N2840/206—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES having multiple IRES
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Transplantation (AREA)
- Developmental Biology & Embryology (AREA)
- Plant Pathology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Prostheses (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261649876P | 2012-05-21 | 2012-05-21 | |
US201361798229P | 2013-03-15 | 2013-03-15 | |
EP13794196.9A EP2852671B1 (en) | 2012-05-21 | 2013-05-21 | Generation of human ips cells by a synthetic self- replicative rna |
PCT/US2013/041980 WO2013177133A2 (en) | 2012-05-21 | 2013-05-21 | Generation of human ips cells by a synthetic self- replicative rna |
Publications (1)
Publication Number | Publication Date |
---|---|
PL2852671T3 true PL2852671T3 (pl) | 2019-06-28 |
Family
ID=49624495
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL13794196T PL2852671T3 (pl) | 2012-05-21 | 2013-05-21 | Wytwarzanie ludzkich komórek ips z użyciem syntetycznego samoreplikującego się rna |
Country Status (14)
Country | Link |
---|---|
US (4) | US9862930B2 (pl) |
EP (1) | EP2852671B1 (pl) |
JP (1) | JP6396893B2 (pl) |
CN (1) | CN104508131B (pl) |
AU (1) | AU2013266496B2 (pl) |
CA (1) | CA2873964A1 (pl) |
DK (1) | DK2852671T3 (pl) |
ES (1) | ES2698527T3 (pl) |
HU (1) | HUE041853T2 (pl) |
IL (2) | IL235628B (pl) |
PL (1) | PL2852671T3 (pl) |
PT (1) | PT2852671T (pl) |
SG (1) | SG11201407595UA (pl) |
WO (1) | WO2013177133A2 (pl) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016011203A1 (en) | 2014-07-15 | 2016-01-21 | Life Technologies Corporation | Compositions with lipid aggregates and methods for efficient delivery of molecules to cells |
SG11201804197RA (en) | 2015-11-18 | 2018-06-28 | Orbis Health Solutions Llc | T7 alpha viral vector system |
JPWO2018155620A1 (ja) * | 2017-02-24 | 2020-01-09 | 剛士 田邊 | 神経系細胞の作製方法 |
JP7146211B2 (ja) * | 2017-02-24 | 2022-10-04 | 剛士 田邊 | 人工多能性幹細胞の作製方法 |
CA3068917A1 (en) * | 2017-07-05 | 2019-01-10 | Wisconsin Alumni Research Foundation | Mineral coated microparticles for co-delivery of anti-inflammatory molecules with nucleic acids to improve gene delivery outcomes |
CN111094549A (zh) * | 2017-09-13 | 2020-05-01 | 生物技术Rna制药有限公司 | 用于将体细胞重编程的rna复制子 |
US11229699B2 (en) | 2017-11-06 | 2022-01-25 | Intervet Inc. | Feline calicivirus vaccine |
EP3719133A4 (en) * | 2017-11-30 | 2021-08-11 | I Peace, Inc. | METHOD FOR PRODUCING NERVOUS CELLS |
KR102143320B1 (ko) | 2018-08-28 | 2020-08-12 | 주식회사 스템랩 | 합성 메신저 rna를 이용하여 소변세포를 신경줄기세포로 직접 역분화하는 방법 |
MX2021004032A (es) * | 2018-10-08 | 2021-07-06 | Janssen Pharmaceuticals Inc | Replicones basados en alfavirus para la administracion de bioterapeuticos. |
WO2020146690A1 (en) * | 2019-01-10 | 2020-07-16 | Massachusetts Institute Of Technology | Methods for in vitro evolution of rna replicons |
JP2022538847A (ja) * | 2019-06-27 | 2022-09-06 | イーエムディ・ミリポア・コーポレイション | 不死化タンパク質を発現する自己複製性rnaベクターによる細胞増殖 |
KR20220129567A (ko) | 2019-12-31 | 2022-09-23 | 엘릭서젠 쎄라퓨틱스, 인크. | 핵산 및 단백질의 세포 및 조직으로의 온도-기반 일시적 전달 |
CN115484990A (zh) | 2020-03-12 | 2022-12-16 | 基础科学研究院 | 诱导具有基因组序列变异的细胞凋亡的组合物及使用组合物诱导细胞凋亡的方法 |
WO2022050419A1 (ja) * | 2020-09-04 | 2022-03-10 | Heartseed株式会社 | iPS細胞の品質改善剤、iPS細胞の製造方法、iPS細胞、及びiPS細胞製造用組成物 |
CN112458064A (zh) * | 2020-11-20 | 2021-03-09 | 广西大学 | 盖他病毒全长感染性克隆、复制子***及其制备和应用 |
CN112852841A (zh) * | 2021-02-03 | 2021-05-28 | 郑州大学 | 一种高效表达目的蛋白的顺式复制子rna构建体 |
WO2022204567A1 (en) | 2021-03-25 | 2022-09-29 | Bluerock Therapeutics Lp | Methods for obtaining induced pluripotent stem cells |
WO2022234268A1 (en) * | 2021-05-04 | 2022-11-10 | Mogrify Limited | Cell conversion |
US20230044997A1 (en) * | 2021-07-15 | 2023-02-09 | Turn Biotechnologies, Inc. | Synthetic, persistent rna constructs and methods of use for cell rejuvenation and for treatment |
WO2023288285A1 (en) * | 2021-07-15 | 2023-01-19 | Turn Biotechnologies, Inc. | Polycistronic expression vectors |
US20230046606A1 (en) * | 2021-07-15 | 2023-02-16 | Turn Biotechnologies, Inc. | Synthetic, persistent rna constructs with on/off mechanism for controlled expression and methods of use |
CA3240645A1 (en) * | 2021-12-20 | 2023-06-29 | Melissa Carpenter | Compositions and methods for cellular reprogramming using circular rna |
TW202400252A (zh) | 2022-04-28 | 2024-01-01 | 美商藍岩醫療公司 | 用於安全基因組整合之新位點及其使用方法 |
US20240082425A1 (en) | 2022-06-23 | 2024-03-14 | Turn Biotechnologies, Inc. | Lipid structures and compositions comprising same |
WO2024129743A2 (en) | 2022-12-13 | 2024-06-20 | Bluerock Therapeutics Lp | Engineered type v rna programmable endonucleases and their uses |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
EP1046421B8 (en) | 1990-12-06 | 2006-01-11 | Affymetrix, Inc. (a Delaware Corporation) | Methods and reagents for very large scale immobilized polymer synthesis |
ES2301178T3 (es) * | 1996-04-05 | 2008-06-16 | Novartis Vaccines & Diagnostic | Vectores basados en alfavirus recombinantes con inhibicion reducida de la sintesis macromolecular celular. |
US5811407A (en) * | 1997-02-19 | 1998-09-22 | The University Of North Carolina At Chapel Hill | System for the in vivo delivery and expression of heterologous genes in the bone marrow |
US20030232324A1 (en) | 2001-05-31 | 2003-12-18 | Chiron Corporation | Chimeric alphavirus replicon particles |
DE60233061D1 (de) | 2001-09-06 | 2009-09-03 | Alphavax Inc | Alphavirus replikon-vektorsysteme |
EP1386926A1 (en) | 2002-07-29 | 2004-02-04 | Bioxtal | Methods for producing labelled recombinant polypeptides and uses thereof |
US20050271639A1 (en) | 2002-08-22 | 2005-12-08 | Penn Marc S | Genetically engineered cells for therapeutic applications |
US7078218B2 (en) | 2002-12-13 | 2006-07-18 | Alphavax, Inc. | Alphavirus particles and methods for preparation |
CA2518546C (en) | 2003-03-20 | 2012-11-13 | Alphavax, Inc. | Improved alphavirus replicons and helper constructs |
US20060198854A1 (en) | 2004-12-28 | 2006-09-07 | Peter Pushko | Vector platforms derived from the alphavirus vaccines |
WO2009067563A1 (en) | 2007-11-19 | 2009-05-28 | The Regents Of The University Of California | Generation of pluripotent cells from fibroblasts |
EP2072618A1 (en) * | 2007-12-14 | 2009-06-24 | Johannes Gutenberg-Universität Mainz | Use of RNA for reprogramming somatic cells |
GB0801215D0 (en) * | 2008-01-23 | 2008-02-27 | Univ Sheffield | Cell re-programming |
JP2011516042A (ja) | 2008-03-17 | 2011-05-26 | へルムホルツ・ツェントルム・ミュンヘン−ドイチェス・フォルシュングスツェントルム・ヒューア・ゲズントハイト・ウント・ウムヴェルト(ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング) | 部位特異的組み換えを用いて無ベクター誘導多能性幹(iPS)細胞を作製するベクターおよびその方法 |
US9497943B2 (en) * | 2008-06-13 | 2016-11-22 | Whitehead Institute For Biomedical Research | Nucleic acid constructs encoding reprogramming factors linked by self-cleaving peptides |
WO2010028019A2 (en) | 2008-09-03 | 2010-03-11 | The General Hospital Corporation | Direct reprogramming of somatic cells using non-integrating vectors |
EP2401372A4 (en) * | 2009-02-27 | 2012-09-19 | Univ Kyoto | NEW NUCLEAR REPROGRAMMING SUBSTANCE |
WO2010118244A1 (en) | 2009-04-08 | 2010-10-14 | Alphavax, Inc. | Alphavirus Replicon Particles Expressing TRP2 |
US8609417B2 (en) | 2009-04-13 | 2013-12-17 | The Regents Of The University Of California | Methods and compositions for stem cell cultures |
WO2011109612A2 (en) * | 2010-03-03 | 2011-09-09 | The General Hospital Corporation | Method for selecting an ips cell |
CA2796464C (en) * | 2010-04-16 | 2021-08-03 | Immune Disease Institute, Inc. | Sustained polypeptide expression from synthetic, modified rnas and uses thereof |
TR201809547T4 (tr) | 2012-11-09 | 2018-07-23 | Biontech Rna Pharmaceuticals Gmbh | Hücresel RNA ifadesine yönelik yöntem. |
-
2013
- 2013-05-21 CN CN201380038648.1A patent/CN104508131B/zh active Active
- 2013-05-21 CA CA2873964A patent/CA2873964A1/en active Pending
- 2013-05-21 DK DK13794196.9T patent/DK2852671T3/en active
- 2013-05-21 HU HUE13794196A patent/HUE041853T2/hu unknown
- 2013-05-21 US US14/402,924 patent/US9862930B2/en active Active
- 2013-05-21 ES ES13794196T patent/ES2698527T3/es active Active
- 2013-05-21 EP EP13794196.9A patent/EP2852671B1/en active Active
- 2013-05-21 SG SG11201407595UA patent/SG11201407595UA/en unknown
- 2013-05-21 WO PCT/US2013/041980 patent/WO2013177133A2/en active Application Filing
- 2013-05-21 PT PT13794196T patent/PT2852671T/pt unknown
- 2013-05-21 AU AU2013266496A patent/AU2013266496B2/en active Active
- 2013-05-21 JP JP2015514104A patent/JP6396893B2/ja active Active
- 2013-05-21 PL PL13794196T patent/PL2852671T3/pl unknown
-
2014
- 2014-11-11 IL IL235628A patent/IL235628B/en active IP Right Grant
-
2018
- 2018-01-02 US US15/860,356 patent/US10370646B2/en active Active
-
2019
- 2019-07-18 US US16/515,767 patent/US10793833B2/en active Active
-
2020
- 2020-02-26 IL IL272917A patent/IL272917A/en unknown
- 2020-09-18 US US17/025,836 patent/US20210108179A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CA2873964A1 (en) | 2013-11-28 |
WO2013177133A3 (en) | 2014-03-20 |
CN104508131B (zh) | 2018-11-23 |
AU2013266496A1 (en) | 2014-11-27 |
US20210108179A1 (en) | 2021-04-15 |
EP2852671A4 (en) | 2015-12-23 |
SG11201407595UA (en) | 2014-12-30 |
EP2852671B1 (en) | 2018-08-22 |
PT2852671T (pt) | 2018-11-29 |
JP2015519898A (ja) | 2015-07-16 |
WO2013177133A2 (en) | 2013-11-28 |
US20190338252A1 (en) | 2019-11-07 |
IL272917A (en) | 2020-04-30 |
JP6396893B2 (ja) | 2018-09-26 |
ES2698527T3 (es) | 2019-02-05 |
US10370646B2 (en) | 2019-08-06 |
EP2852671A2 (en) | 2015-04-01 |
US20180216079A1 (en) | 2018-08-02 |
AU2013266496B2 (en) | 2018-08-09 |
HUE041853T2 (hu) | 2019-05-28 |
US10793833B2 (en) | 2020-10-06 |
DK2852671T3 (en) | 2018-12-10 |
CN104508131A (zh) | 2015-04-08 |
IL235628A0 (en) | 2015-01-29 |
IL235628B (en) | 2020-03-31 |
US20150159143A1 (en) | 2015-06-11 |
US9862930B2 (en) | 2018-01-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL272917A (en) | Generation of human induced pluripotent stem cells using artificial self-replicating RNA | |
HK1212388A1 (en) | Methods of tissue generation | |
HK1212261A1 (en) | Methods of tissue generation | |
SG11201501729TA (en) | Three-dimensional cell culturing | |
PL2741535T3 (pl) | Sposób prowadzenia umieszczania nowych małych komórek | |
EP2815546A4 (en) | CONSTRUCTION OF A LARGE SCALE DVPN | |
EP2764325A4 (en) | USE OF A VIDEOGRAMMETRY FOR THE MANUFACTURE OF PARTS | |
GB201222882D0 (en) | Ultrasound generation | |
EP2790628A4 (en) | DIAPER | |
EP2667383A4 (en) | PRESSURE WATER REACTOR | |
GB2489486B (en) | Improvements relating to construction | |
EP2831741A4 (en) | PREPARATION OF A TEST CENTERED MODEL OF ONE APPLICATION | |
EP2814944A4 (en) | BIOMASS YIELD GENES | |
ZA201205924B (en) | Reactor | |
EP2793379A4 (en) | GENERATOR | |
BR112013028889A2 (pt) | recheio de reator | |
GB2493964B (en) | Cultivator | |
GB201104001D0 (en) | Improvements to goggles | |
ZA201402237B (en) | Generator | |
EP2809685A4 (en) | ELECTROCHEMICAL SYNTHESIS OF CHLORO-CHITOSAN | |
GB201203038D0 (en) | Waveform generation | |
EP2736056A4 (en) | REACTOR | |
EP2700402A4 (en) | NEW USES OF LICOCHALCONE A | |
CO6811845A2 (es) | Reactor de recuperación | |
GB2507762B (en) | Improvements to dartboards |